ATRX Adhera Therapeutics

Adhera Therapeutics Inc. and its wholly-owned subsidiaries, MDRNA Research Inc. (“MDRNA”), Cequent Pharmaceuticals Inc. (“Cequent”), Atossa Healthcare Inc. (“Atossa”), and IThenaPharma Inc. (“IThena”) (collectively “Adhera,” the “Company,” “we,” “our,” or “us”), is an emerging specialty biotech company that, to the extent that resources and opportunities become available, is strategically evolving focus in anticipation of a return to a drug discovery and development company, and a departure from active commercialization and promotion of hypertension treatment options in the U.S. market. Previously throughout most of 2019, Adhera Therapeutics was a commercially focused entity that leveraged innovative distribution models and technologies to improve the quality of care for patients in the United States suffering from chronic and acute diseases with a focus on fixed dose combination therapies in hypertension. These efforts were primarily focused on Prestalia® , a single-pill FDC of perindopril arginine and amlodipine besylate, which we began marketing in June of 2018. Prestalia was developed in coordination with Les Laboratories, Servier, a French pharmaceutical conglomerate, that sells the formulation outside the United States under the brand names Coveram® . Prestalia was approved by the U.S. Food and Drug Administration (“FDA”) in January 2015, and was distributed through our patented DyrctAxess platform.

Company profile

Nancy R. Phelan
Fiscal year end
Former names
IRS number

ATRX stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


24 May 21
2 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 1K 1K 1K 1K 1K 1K
Cash burn (monthly) (positive/no burn) 5.33K 36.67K 68.67K 15.33K 20K
Cash used (since last report) n/a 21.79K 149.8K 280.54K 62.64K 81.71K
Cash remaining n/a -20.79K -148.8K -279.54K -61.64K -80.71K
Runway (months of cash) n/a -3.9 -4.1 -4.1 -4.0 -4.0

Beta Read what these cash burn values mean

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

0.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1 1
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 1 1
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Huntington National Bank 1 $0 0.0%
Largest transactions
Shares Bought/sold Change
Huntington National Bank 1 0 0.0%

Financial report summary

Content analysis
H.S. sophomore Avg
New words: Antidilutive, authorized, BCF, binomial, borrowed, calendar, Carlo, case, component, declared, deemed, deferred, delay, derivative, embedded, emerging, GmbH, goodwill, host, indexed, instrument, insurance, issuer, Junior, liposomal, Monte, NDA, notional, Novosom, PFUFA, previously, quantitative, readily, receipt, redeemable, regulatory, remove, repricing, retired, Schedule, scope, separated, separation, simplify, Step, Subtopic, subtracting, sum, tax, traditional, treated, Trond, volatility
Removed: accrual, affiliate, annually, assistance, assumed, audited, Biofarma, book, bought, Boulevard, Carolina, Chairman, channel, commercial, Comparatively, compare, contractual, contractually, corporate, credit, customer, dating, decision, departure, detailed, determine, determining, digit, disclose, dispensed, divest, Durham, efficiency, Emerson, Emperor, empower, enhanced, Erik, estimate, evolving, experience, expiration, found, greater, group, health, Hub, intangible, inventory, key, landlord, leased, leasing, lessee, list, located, low, manager, medicine, modify, monthly, network, North, offer, offering, Office, optimal, owner, patient, payer, PDUFA, Pharma, pharmacy, point, policy, practice, prescribed, prescription, projected, promotion, provision, range, receive, record, reduce, rejected, rent, retained, returned, review, satisfied, settled, shelf, shipment, shipping, single, sixty, space, subsequently, substantially, Suite, technology, testing, ThreeCo, trademark, transfer, transferring, undiscounted, unrealized, variable, wholesale